Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Trevi Therapeutics将在ATS 2024会议上公布Haduvio治疗慢性咳嗽的第二阶段结果
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.
Trevi Therapeutics, Inc.（纳斯达克股票代码：TRVI）是一家处于临床阶段的生物制药公司，该公司正在开发用于治疗特发性肺纤维化（IPF）和难治性慢性咳嗽（RCC）的研究性疗法Haduvio（口服纳布啡ER），今天宣布，CANAL二期试验的数据将在2024年美国胸科学会（ATS）国际会议上公布会议将于5月17日至22日在加利福尼亚州圣地亚哥举行。演讲将于5月19日举行。